Medizin - Open Access LMU - Teil 13/22

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?


Listen Later

Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy. We prospectively studied serial kinetics of serum CA 19-9 levels of patients with locally advanced or metastatic disease treated with gemcitabine and cisplatin. Patients and Methods: Enrolled in the study were 87 patients (female/male = 26/61; stage III/IV disease = 24/63). Patients received gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 plus cisplatin 50 mg/m(2) on days 1 and 15, every 4 weeks. Serum samples were collected at the onset of chemotherapy and before the start of a new treatment cycle (day 28). Results: 77 of 87 patients (88.5%) with initially elevated CA 19-9 levels were included for evaluation. According to imaging criteria, 4 (5.2%) achieved a complete remission and 11 (14.3%) achieved partial remission, yielding an overall response rate of 19.5%. 43 (55.8%) patients were CA 19-9 responders, defined by greater than or equal to50% decrease in CA 19-9 serum levels within 2 months after treatment initiation. Except for one, all patients who had responded by imaging criteria (n = 14) fulfilled the criterion of a CA 19-9 responder. Despite being characterized as non-responders by CT-imaging criteria (stable/progressive disease), 29 patients were classified as CA 19-9 responders (positive predictive value 32.5%). Independent of the response evaluation by CT, CA 19-9 responders survived significantly longer than CA 19-9 non-responders (295 d; 95% CI: 285-445 vs. 174 d; 95% CI: 134-198; p = 0.022). Conclusion: CA 19-9 kinetics in serum serve as an early and reliable indicator of response and help to predict survival in patients with advanced pancreatic cancer receiving effective treatment with gemcitabine and cisplatin.
...more
View all episodesView all episodes
Download on the App Store

Medizin - Open Access LMU - Teil 13/22By Ludwig-Maximilians-Universität München


More shows like Medizin - Open Access LMU - Teil 13/22

View all
Tonspur Forschung by Annik Rubens

Tonspur Forschung

3 Listeners

Theoretical Physics Schools (ASC) by The Arnold Sommerfeld Center for Theoretical Physics (ASC)

Theoretical Physics Schools (ASC)

2 Listeners

Physik - Open Access LMU - Teil 01/02 by Ludwig-Maximilians-Universität München

Physik - Open Access LMU - Teil 01/02

1 Listeners

MCMP – Mathematical Philosophy (Archive 2011/12) by MCMP Team

MCMP – Mathematical Philosophy (Archive 2011/12)

6 Listeners

Hegel lectures by Robert Brandom, LMU Munich by Robert Brandom, Axel Hutter

Hegel lectures by Robert Brandom, LMU Munich

6 Listeners

MCMP – Philosophy of Science by MCMP Team

MCMP – Philosophy of Science

1 Listeners

MCMP – Epistemology by MCMP Team

MCMP – Epistemology

0 Listeners

Epistemology and Philosophy of Science: Prof. Dr. Stephan Hartmann – HD by Ludwig-Maximilians-Universität München

Epistemology and Philosophy of Science: Prof. Dr. Stephan Hartmann – HD

1 Listeners

Sommerfeld Lecture Series (ASC) by The Arnold Sommerfeld Center for Theoretical Physics (ASC)

Sommerfeld Lecture Series (ASC)

0 Listeners

Medizin - Open Access LMU - Teil 14/22 by Ludwig-Maximilians-Universität München

Medizin - Open Access LMU - Teil 14/22

0 Listeners